Valion Bio (VBIO) Liabilities from Discontinued Operations (2024 - 2026)
Valion Bio (VBIO) posted quarterly Liabilities from Discontinued Operations of 6000.0 for Q4 2025, down 60.0% year-over-year from 15000.0 in Q4 2024, and down 60.0% quarter-over-quarter from 15000.0 in Q4 2024.
Valion Bio (VBIO) Liabilities from Discontinued Operations (2024 - 2026) Analysis & Trends
Valion Bio's Liabilities from Discontinued Operations history runs 2 years deep, the most recent figure standing at 6000.0 for Q4 2025.
- In Q4 2025, Liabilities from Discontinued Operations fell 60.0% year-over-year to 6000.0; the TTM figure through Dec 2025 stood at 6000.0 (down 60.0% YoY), while the FY2025 annual figure was 6000.0, down 60.0% from the prior year.
- Liabilities from Discontinued Operations for Q4 2025 stood at 6000.0, down from 15000.0 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was 15000.0 in Q4 2024, with the low at 6000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43,000.00 |
| Jun 30, 2026 | 43,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Dec 31, 2024 | 15,000.00 |